Abstract 3698
Background
Patient-centered endpoints, overall survival (OS) and QoL (where the benefit is detectable by the patient as an improvement in symptoms or functional capacity), are considered valid “direct” endpoints by the FDA. While EORTC-C30 is an accepted indicator of QoL, there is no accepted standard for time to QoL status improvement, nor any accepted standard of analysis for EORTC-C30 data.
Methods
A single-group, open-label, feasibility study was performed to assess QoL status in HCC patients exposed to modulated EMF at patient-specific frequencies. A 120-min outpatient EMF exposure procedure was performed every 30 days until significant QoL deterioration or death. An oral spoon-shaped RF antenna applicator was used to apply EMF while individuals were kept in supine position. EORTC-C30 v3.0 questionnaires were answered by individuals immediately prior to every EMF exposure. The 17 QoL parameters were divided into those measuring improvement (G+ functional scales and global health status/QOL) and those measuring deterioration (G- symptom scales). QoL index was calculated as (mean G+) – (mean G-). Different QoL index calculations were made using three groups of QoL parameters: all 17 QoL parameters, 15 QoL parameters (removing Functional scales and Symptom scales) and 3 QoL parameters (restricted to Functional scales, Symptom scales and Global health status/QOL). A change of +/-5% in QoL index was considered a clinically relevant improvement/deterioration in QoL status.
Results
42 HCC were exposed to 151 EMF procedures. 4,530 QoL data points were collected for analysis, with 0.1% missing data. QoL index was measured at baseline and 30 days after the baseline exposure procedure. Using the 3 QoL index calculation methods (17 QoL, 15 QoL and 3 QoL) measured 30 days from the baseline exposure, QoL status improved in 63%, 59% and 74% of HCC patients respectively.
Conclusions
Rapid and significant improvement in QoL status in HCC patients exposed to EMF was detected within 30 days of exposure regardless of the QoL index calculation methods used.
Clinical trial identification
NCT 01686412.
Editorial acknowledgement
Luiz Fernando Reis PhD, Research Director Hospital Sírio Libanês, São Paulo, Brazil, Riad Younes MD and Bertram Wiedenmann PhD MD.
Legal entity responsible for the study
Hospital Sírio Libanês.
Funding
Has not received any funding.
Disclosure
F.P. Costa: Leadership role: Autem Medical. A. Iemma: Honoraria (institution): Autem Medical. F. Soares: Honoraria (institution): Autem Medical. J. Tuszynski: Advisory / Consultancy: Autem Medical. All other authors have declared no conflicts of interest.
Resources from the same session
681 - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer
Presenter: Gouji Toyokawa
Session: Poster Display session 1
Resources:
Abstract
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract